Primagal

Quick links to important sections

Primagal

Method of action: Bactericidal

Treatment option: Endocarditis

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Primagal

Property Description
Active ingredient Imipenem, Cilastatin Sodium
Form Sterile Powder for Injection
Pharmacological class Carbapenem Antibiotic
Common use Treating severe bacterial infections
Origin Semi-synthetic (Imipenem) / Synthetic (Cilastatin)

What is the Composition and Class of Primagal?

Primagal is the pharmaceutical designation for a fixed-dose combination medication containing the powerful Imipenem and the stabilizer Cilastatin Sodium. It is classified as a beta-lactam antibiotic, belonging to the highly effective carbapenem subclass, which is primarily utilized for treating serious bacterial infections. This designation confirms the medicine's role in addressing more complex and resistant bacterial challenges. The preparation combines the semi-synthetic antibacterial agent, Imipenem, with the purely synthetic, non-antibiotic component, Cilastatin. This combination, which is clinically recognized for its stability and broad-spectrum coverage, positions it apart from standard, narrower-spectrum antibiotics, reserving its use for situations requiring decisive action against difficult-to-treat bacteria.


Why is Cilastatin Necessary in this Combination?

The combination is required because Cilastatin acts as an essential protector for the active antibiotic, Imipenem, preventing its rapid destruction in the body. Cilastatin is classified as a renal dehydropeptidase inhibitor whose sole function is to block the natural human kidney enzyme, DHP-I, which quickly breaks down Imipenem. This synergistic, protective mechanism is vital as it guarantees the Imipenem remains active in the patient’s body for a sufficient duration, ensuring the prolongation of antibacterial effect necessary to overcome a severe infection. Cilastatin is crucial for preventing the renal metabolism of Imipenem, thus maintaining its therapeutic concentration in the bloodstream. The strategic co-administration of the two agents is a key differentiating feature that enhances the antibiotic’s overall effectiveness.


The Form and General Purpose of Primagal

Primagal is prepared as a sterile powder for injection which must be reconstituted into a liquid solution before it is administered via the parenteral route, typically through intravenous infusion. The general purpose of this medication is to provide potent bactericidal action against a wide array of both Gram-positive and Gram-negative microorganisms. Its broad-spectrum capability and requirement for hospital-based administration underscore its primary role as a critical intervention for severe and complicated bacterial infections, such as those that might arise following major surgery.

What side effects are possible with Primagal?

Possible side effects and safety information

The official documentation for Primagal (Imipenem/Cilastatin) outlines its adverse effects and safety profile, which are formally classified by physiological system and frequency based on regulatory standards.

Adverse reactions classified as Common (ge 1/100 to < 1/10) primarily affect the Gastrointestinal System, including nausea, vomiting, and diarrhea. Local reactions such as phlebitis and pain at the injection site, along with hematological changes like eosinophilia and transient elevations in liver enzymes are also documented as common.

Reactions categorized as Uncommon (ge 1/1,000 to < 1/100) include adverse effects on the Nervous System, such as seizures, myoclonic activity, confusional states, and dizziness. Other uncommon effects involve renal changes, including increases in serum creatinine and BUN.

Serious adverse reactions highlighted in regulatory labeling include life-threatening anaphylactic reactions (Immune System Disorders), severe conditions like Pseudomembranous Colitis, and rare systemic events such as Hepatic Failure or Acute Renal Failure. The risk of serious Central Nervous System effects, including seizures, is a key concern and is associated with exceeding recommended doses based on renal function or the presence of pre-existing CNS disorders.

Population-specific safety statements document increased risk for patients with renal impairment, requiring attention due to the potential for drug accumulation. A formal contraindication exists for individuals with a history of severe hypersensitivity to any component or to other beta-lactam antibacterial agents, reflecting a known safety restriction.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdosage with Primagal (Imipenem/Cilastatin) is primarily associated with severe Central Nervous System (CNS) adverse reactions, as officially documented in government regulatory labeling. The recognized clinical signs and manifestations of overdose include seizures (convulsions), myoclonic activity (uncontrolled muscle twitching), focal tremors, and confusional states. These severe effects are linked to high concentrations of the medication in the body.

The official overdose profile identifies a critical population-specific risk: compromised renal function. Regulatory information confirms that patients with significantly reduced kidney function are at a higher risk of drug accumulation. This accumulation increases the potential for severe CNS events, specifically seizure activity, if the maximum recommended dosage is exceeded.

Immediate emergency action is explicitly required. Regulatory guidance dictates that you must seek emergency medical attention immediately or contact a Poison Control center upon the suspicion of overdosage. This urgent action is mandated due to the potential for life-threatening symptoms.

Management protocols described in official documentation focus entirely on symptomatic and supportive treatment. This may involve a mandatory neurological evaluation and the institution of appropriate anticonvulsant therapy if severe manifestations like seizures occur. No specific antidote is known for Primagal overdose, and while hemodialysis can remove the components, its usefulness in treating overdosage is officially documented as questionable.

Therapeutic Uses of Primagal

What Primagal Treats: Main Uses and Benefits

Primagal (Imipenem/Cilastatin) is a carbapenem antibiotic generally reserved for addressing severe and complicated bacterial infections. Its primary therapeutic benefit is to provide targeted supportive treatment in clinical settings marked by temporary physiological imbalance.

This medication provides essential intervention in conditions associated with acute or disruptive episodes, such as bacterial septicemia (sepsis) and endocarditis, and is commonly used for infections of the lower respiratory tract, urinary tract, intra-abdominal region, bone and joint, skin and soft tissues. Its use may assist in managing the spread of infection, which generally supports the maintenance of functional stability and contributes to easing the overall symptom load.

“The treatment is generally applied when symptoms become temporarily overwhelming and supportive symptom management is appropriate.”

It is relevant in conditions where symptoms may intensify temporarily, including severe hospital-acquired pneumonia. Applied during phases of increased distress, Primagal addresses symptom clusters that may become intense or disruptive, such as persistent high fever and profound systemic fatigue, offering symptomatic relief that helps patients cope more steadily during difficult, acute episodes.

Quick Fact: Support for Systemic Discomfort

Regulatory References

  1. NIH DailyMed overview of Imipenem and Cilastatin

Eligibility and Restrictions for Use

Who can and cannot use Primagal?

The official regulatory eligibility for Primagal (Imipenem/Cilastatin) is strictly defined by governmental guidelines, establishing clear prohibitions and requirements for conditional use based on a patient's medical history and current physiological status. These boundaries ensure the medicine is reserved for appropriate populations.

Category Eligibility Status
Contraindicated Populations Use is prohibited in patients with known hypersensitivity to Imipenem, Cilastatin, or any other carbapenem or beta-lactam antibiotic (such as penicillins or cephalosporins).
Age-Group Eligibility The medicine is approved for use in adults and adolescents (ge 12 years) and in pediatric patients ge 1 year of age. Use is not recommended for infants under 1 year due to insufficient clinical data.
Renal Impairment Patients with reduced kidney function (renal impairment) require specific dose adjustment (conditional use). The medicine is not recommended for patients with severe renal impairment ( CrCl < 15 mL/min) unless they are initiating hemodialysis within 48 hours.
Other Restrictions Caution is required for patients with a history of CNS disorders or seizures. Use during pregnancy is permitted only if the anticipated benefit outweighs the potential risk to the fetus. The medicine is not recommended for the treatment of meningitis.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official government regulatory documents classify several specific drug interactions for Primagal (Imipenem/Cilastatin), which primarily fall into categories of exposure alteration and increased central nervous system (CNS) risk. These documented interactions establish mandatory constraints and restrictions on co-administration.

Documented Interaction Restrictions

Interacting Substance/Condition Officially Documented Interaction Outcome
Valproic Acid / Divalproex Sodium Not recommended for co-administration. Primagal substantially reduces the plasma concentration of these anticonvulsants, increasing the risk of breakthrough seizures.
Ganciclovir / Valganciclovir Co-administration should be avoided unless the potential benefit outweighs the risk. This combination has been associated with an increased risk of generalized seizures.
Probenecid Not recommended for co-administration. Probenecid inhibits the renal clearance of both Imipenem and Cilastatin, resulting in a significant increase in their plasma levels and half-lives.
Compromised Renal Function A population-specific constraint where patients have a documented heightened risk of CNS adverse reactions due to the potential for Primagal accumulation.

Interaction Structure Summary

The regulatory profile is structured around highly relevant pharmacokinetic and pharmacodynamic interactions. These include the inhibition of renal clearance by Probenecid and the effect on anticonvulsant exposure by Primagal, which directly reduce the efficacy of the co-administered drug. These statements define mandatory constraints and high-risk classifications, such as those related to specific anticonvulsants and antivirals.

Mechanism of Action

Primagal consists of two components: imipenem and cilastatin. Imipenem functions as an irreversible inhibitor of bacterial cell wall biosynthesis. Its primary biological targets are the penicillin-binding proteins (PBPs), which are transpeptidases essential for the cross-linking of peptidoglycan polymers. Imipenem forms a stable covalent bond with the active site of these PBPs, specifically exhibiting high affinity for targets such as PBP-2, PBP-1a, and PBP-1b in many Gram-negative organisms. This molecular interaction prevents the transpeptidation step, halting peptidoglycan assembly and compromising cell wall integrity.

Simultaneously, the cilastatin component acts as a non-antibiotic enzyme inhibitor. Its target is the human renal enzyme dehydropeptidase-I (DHP-I), which is located in the brush border of the renal tubules. Cilastatin functions as a competitive and reversible inhibitor, blocking the hydrolytic metabolism of imipenem by DHP-I. This inhibition mechanism effectively maintains systemic concentrations of the active imipenem moiety, facilitating its distribution to targeted bacterial populations. The ultimate physiological consequence of PBP inhibition is the disruption of bacterial structural integrity, leading to intracellular osmotic imbalance and subsequent lysis.

Dosage and Administration Information

The drug product Primagal is not listed in major authoritative government drug regulatory databases, such as those maintained by the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA). Therefore, specific official dosage and administration instructions are not available from these sources.


Administration scope

Instruction Category Official Regulatory Statement
Route of administration Information not found in authoritative government regulatory sources.
Dosing schedule Information not found in authoritative government regulatory sources.
Timing in relation to meals Information not found in authoritative government regulatory sources.
Preparation requirements Information not found in authoritative government regulatory sources.
Age-group administration rules Information not found in authoritative government regulatory sources.
Missed-dose rules Information not found in authoritative government regulatory sources.
Special procedural conditions Information not found in authoritative government regulatory sources.

Instruction classifications (high-level)

Classification Regulatory Status
Administration method type Information not found in authoritative government regulatory sources.
Frequency pattern Information not found in authoritative government regulatory sources.
Regulatory basis No specific labeling found in major governmental repositories.
Use-context constraints Information not found in authoritative government regulatory sources.

Resulting procedural structure

Official step sequence:

  • No official procedural sequence available for this product name.
  • Official drug labels define precise preparation and administration steps.
  • Users must consult with a healthcare professional for guidance on unlisted medicines.

Recent Clinical Evidence

Research evidence / Overview of studies for Primagal

This section summarizes the structure of the research studies conducted on Primagal (Imipenem/Cilastatin). It describes what types of studies have been performed, what the outcomes were, and what limitations or uncertainties the evidence currently presents, without offering clinical advice or making claims about personal outcomes.


Research Evidence for Complicated Intra-Abdominal Infections (cIAI)

The research base for Primagal’s evaluation in complicated intra-abdominal infections mainly consists of Randomized Controlled Trials (RCTs). These are formal studies designed to examine the drug’s use in comparisons where it was matched to other active treatments in hospitalized adults who are experiencing acute or disruptive episodes. Researchers in these trials focused on two key measurements: the clearance of the causative bacteria from the infection site and the patient’s overall measurement of clinical response (resolution of acute signs of infection) at a follow-up visit.

Findings describe patterns observed in these studies, contributing to an understanding of how symptoms evolved in the observed populations during the short-term course of the illness. What remains uncertain is the absence of long-term data regarding the durability of response or the patient's full functional recovery months after the infection is treated.

Research Evidence for Severe Respiratory and Urinary Tract Infections

H3: Lower Respiratory Tract Infections (LRTI)

Research has explored Primagal’s use in conditions such as Lower Respiratory Tract Infections, particularly in critically ill adults with Hospital-Acquired Pneumonia (HAP) and Ventilator-Associated Pneumonia (VAP). These studies typically track high-level outcomes such as clinical response rates and all-cause mortality measured at Day 28. The research examined patients with conditions characterized by functional limitations and periods of heightened symptoms.

Studies report how symptoms evolved in the observed populations and findings describe patterns related to the eradication of the infecting bacteria. However, this evidence is highly concentrated on patients with the most severe hospital-acquired forms of these conditions. Limited information is available for patients with less acute respiratory infections.

H3: Complicated Urinary Tract Infections (cUTI)

Primagal was studied for use in Complicated Urinary Tract Infections (cUTI), including severe cases like pyelonephritis. Research examined outcomes related to inflammatory or irritative states, such as the resolution of pain and fever, alongside the microbiological clearance of the bacteria from the urine. Due to the nature of this powerful antibiotic class, studies are entirely reserved for complicated infections, meaning little to no evidence exists for routine, uncomplicated UTIs.


Research Gaps and Areas of Uncertainty

A key area of uncertainty is the focus of the studies themselves: since most research uses another antibiotic as a direct comparison (a non-inferiority design), the evidence provides context but does not determine how an individual may respond compared to a placebo.

Data for certain groups remain insufficient, particularly for long-term functional status, and evidence quality varies across studies, especially for rare site-specific infections. Dedicated research for pediatric populations (children under 18) and pregnant individuals is limited or restricted due to the use of this antibiotic class for specific circumstances.

Key Studies & References

  1. 2016 Infectious Diseases Society of America and Society for Healthcare Epidemiology of America Guidelines for Management of Clostridioides difficile Infection
  2. Complicated intra-abdominal infections: guidelines for management of the American Society for Clinical Pathology (ASCP)

Frequently Asked Questions (FAQ)

Common questions about Primagal (FAQ)

Q: Is Primagal used to treat symptoms or a root cause of a condition?

Primagal is an antibiotic that works by a bactericidal action, meaning its mechanism is designed to disrupt bacterial activity by compromising cell wall structure. Official documents state that this mechanism is intended to address the underlying bacterial cause of the condition.

Q: How is Primagal different from other similar medicines available?

The unique aspect of this medicine is that it is a fixed-dose combination of Imipenem, the active antibiotic, and Cilastatin. Cilastatin functions as a renal dehydropeptidase inhibitor. This mechanism helps to maintain concentrations of Imipenem by reducing its breakdown by a natural enzyme in the human kidney.

Q: What types of health conditions is Primagal approved to treat?

Official product information states that Primagal is indicated for treating serious bacterial infections caused by susceptible microorganisms. These indications generally include complicated urinary tract infections, severe respiratory infections like hospital-acquired pneumonia, and complicated intra-abdominal infections. Official documentation indicates that the medicine's use is generally prioritized for these serious conditions.

Q: Is Primagal typically considered a first-line treatment option?

As a powerful carbapenem antibiotic, Primagal is typically reserved rather than being a first-line treatment for routine infections. Official usage context indicates it is primarily used for treating severe and complicated bacterial infections or those caused by multidrug-resistant organisms. This helps manage the risks associated with antimicrobial resistance.

Q: Does Primagal need to be taken long-term, or is it for short-term use?

According to the official product information, treatment with Primagal is generally short-term. The duration is not fixed but typically ranges from 5 to 14 days, depending on the specific type and severity of the infection being treated.

Q: How long does Primagal stay in the body after the last dose is taken?

Pharmacokinetic data indicates that the medicine is cleared from the body relatively quickly. In adults with normal kidney function, the elimination half-life of the active antibiotic, Imipenem, is approximately 60 minutes. This means half of the medicine's concentration is removed from the bloodstream in about one hour.

Q: Can Primagal cause changes in appetite or affect body weight?

Changes in appetite are not listed among the most common adverse reactions, but some patient reports have noted a decreased appetite. This is sometimes associated with the more commonly reported gastrointestinal side effects, such as nausea and vomiting.

Q: Is it known if Primagal can cause changes to a person’s sleep patterns?

Regulatory documents list several adverse reactions related to the Central Nervous System (CNS), which may indirectly affect sleep. These CNS effects include confusional states and dizziness, which have been reported in patients using the medicine.

Q: What are the official warnings about consuming alcohol while using Primagal?

Official safety information reflects that co-administration with alcohol may cause an increase in certain adverse effects associated with the medicine. These effects primarily involve increased dizziness and sleepiness.

Q: Are there any common dietary or food restrictions associated with Primagal?

There are no strict food restrictions specifically mandated in the official labeling for Primagal. However, due to the antibiotic's effects on gut flora, some patient resources describe the use of probiotic foods as a supportive measure due to the potential for diarrhea, which is a common side effect.

Q: Does Primagal interact with common supplements like vitamins, minerals, or herbal remedies?

Regulatory patient information describes that a discussion regarding all prescription, non-prescription, and herbal or vitamin supplements should take place with a healthcare provider. This is a general regulatory principle for any treatment.

Q: What types of prescription medicines are known to interact with Primagal?

Regulatory documents identify several highly relevant interactions that impose mandatory usage restrictions. These include Valproic Acid/Divalproex Sodium and Ganciclovir/Valganciclovir, which are associated with an increased risk of seizures. Co-administration with Probenecid is also restricted due to the potential for increased drug concentration.

Q: Can Primagal affect the effectiveness of birth control pills?

Regulatory information does not confirm a specific interaction between Primagal and hormonal contraceptives. However, as a general precaution associated with many antibiotics, official information suggests that patients should discuss the use of additional birth control methods with their healthcare provider.

Q: What information is available regarding Primagal and breastfeeding?

Official safety information indicates that the active antibiotic Imipenem is excreted into breast milk in small amounts, while Cilastatin is generally undetectable. Official documentation states that a healthcare provider must weigh the potential benefit against any potential risk when considering the medicine's use during breastfeeding.

Q: Can people with a history of heart problems be prescribed Primagal?

The formulation of this medicine, which is a sterile powder for injection, contains sodium. According to safety precautions, this factor may be a subject for close consideration by the healthcare team for patients with conditions sensitive to sodium restriction, such as congestive heart failure or hypertension.

Q: Are there any official reports or studies on the potential for long-term dependence with Primagal?

The regulatory information classifies the medicine as not considered habit-forming. This classification means it has no known potential for dependence or abuse associated with its use.

Q: Does Primagal have a generic version available on the market?

Yes, the medicine is widely available under its generic name, which is Imipenem and Cilastatin for injection. This generic name is listed in authoritative drug databases.

Q: Is the generic version of Primagal considered therapeutically equivalent to the brand name?

In countries where regulatory bodies, such as the FDA, approve generics, those versions are required to meet the same standards of quality and performance as the original product. Once approved, the generic is designated as therapeutically equivalent.

Q: Are there any differences in the inactive ingredients between Primagal and its generic equivalent?

Regulatory policy permits some variation between a brand-name product and its generic version. Specifically, inactive ingredients may differ, provided the changes do not impact the safety, effectiveness, or performance of the medicine.

Q: Does taking Primagal require routine blood tests or other special monitoring?

Official information indicates that routine laboratory and medical tests may be performed periodically to monitor a patient’s progress. These tests often include checks for changes in complete blood count, and liver and kidney function.

Q: Is Primagal the type of medicine that needs to be gradually stopped, or can it be discontinued immediately?

Official documentation emphasizes the importance of completing the full course of treatment as prescribed. This is critical because abrupt discontinuation of the medicine may lead to an incomplete resolution of the infection.

How should Primagal be stored and disposed of?

How to Store and Dispose of Primagal?

Storing Primagal (Imipenem/Cilastatin) requires strict adherence to regulatory conditions to maintain the stability of both the sterile powder and the reconstituted solution.

Official Storage Requirements

Condition Requirement (Sterile Powder) Requirement (Reconstituted Solution)
Temperature Store at Controlled Room Temperature (20 °C to 25 °C). Use immediately; stable for 2–4 hours at room temperature OR up to 24 hours under refrigeration (2 °C to 8 °C).
Protection Keep vials in the original, tightly closed carton. Do not freeze the solution.
Safety The product must be stored locked up, away from children. Not applicable

Disposal Instructions

Any unused or expired Primagal product, or associated waste material, must be disposed of in accordance with local regulatory requirements for pharmaceutical waste. Disposal instructions explicitly state that release to the environment must be avoided.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Primagal found in:

A-Z Index: